ASCO24 Updates: Claudio Monteiro on Predicting FLAURA2 Outcomes with QSP Modeling

The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most prestigious conferences in the field of oncology. This year, the meeting took place from May 31 to June 4 in Chicago, Illinois. The event gathers oncologists, researchers, and healthcare professionals from around the world to discuss the latest advancements in cancer research, treatment, and patient care. Keynote sessions, research presentations, and panel discussions are typically part of the agenda, providing attendees with valuable insights into emerging trends and innovations in oncology.

This year, OncoDaily was at ASCO 2024 for the first time covering the meeting on-site. We had the pleasure of interviewing researchers who summarized the highlights of their work.

In this video, Claudio Monteiro, Executive Manager at Nova Discovery, discusses his work on ‘Comparing the efficacy of two generations of EGFR-TKIs: An integrated drug-disease mechanistic model approach in EGFR-mutant lung adenocarcinoma.’

I’m Claudio Montero, I’m executive manager at Nova Discovery, a company based in France and doing QSP modelling, so basically mathematical modelling of diseases. And this year at ASCO, I’m presenting a poster with Professor Dioriso on the prospective prediction of FRA2, a phase 3 clinical trial, where we use a mechanistic model of non-small cell lung cancer that we plug with different drug models including Osimertinib, platinum-based chemotherapies and Pemetroxide, and we reproduce the clinical trial setting to predict the results of this trial. So we publish the results three days before official results to be released during the ISLC conference and yeah, that’s it.

More videos and content from ASCO 2024 on OncoDaily.